Autopsy report · NCT01131585

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

“European drug approval.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 128 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Visual Impairment Due to Diabetic Macular Edema

Interventions

Active laser photocoagulation; Sham injections; Ranibizumab 0.5 mg

Participants

128

Sites

34

Countries

Germany

Trials that died the same way

• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (69% match in meaning)
• Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
  “Recent FDA approval of a new drug for the same patient population” (64% match in meaning)
• Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
  “Study Drug was FDA approved Summer 2021” (63% match in meaning)
• The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
  “Pending FDA approval” (62% match in meaning)
• Electrical Impedence Tomography With ENLIGHT2100
  “Device received FDA approval” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.